Rockville, Maryland — According to state and local development sources, Samsung Biologics plans to invest $280 Million to expand in Rockville. The company plans to occupy the new space in Rockville, on or about April 1, 2027. According to the company website Samsung Biologics is a leading global contract development and manufacturing organization (CDMO) that provides end-to-end biopharmaceutical services. The company offers comprehensive solutions ranging from cell line development to final aseptic fill/finish, emphasizing precision and scalability. Driven by continuous innovation and operational excellence, Samsung Biologics aims to be a trusted partner, delivering speed and flexibility in the biopharma industry. They also focus on new modalities like Antibody-Drug Conjugates (ADCs) and mRNA, demonstrating their commitment to advancing biopharmaceutical production.

To learn more about Samsung Biologics, visit https://samsungbiologics.com/

Company Contact:
John Rim, Chief Executive Officer
82 32-455-3114

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.